339 related articles for article (PubMed ID: 29477393)
21. Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report.
Ramsey SD; Willke RJ; Glick H; Reed SD; Augustovski F; Jonsson B; Briggs A; Sullivan SD
Value Health; 2015 Mar; 18(2):161-72. PubMed ID: 25773551
[TBL] [Abstract][Full Text] [Related]
22. Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force report--Part IV.
Mullins CD; Seal B; Seoane-Vazquez E; Sankaranarayanan J; Asche CV; Jayadevappa R; Lee WC; Romanus DK; Wang J; Hay JW; Smeeding J
Value Health; 2010; 13(1):18-24. PubMed ID: 19807903
[TBL] [Abstract][Full Text] [Related]
23. The ICER Value Framework: Integrating Cost Effectiveness and Affordability in the Assessment of Health Care Value.
Pearson SD
Value Health; 2018 Mar; 21(3):258-265. PubMed ID: 29566831
[TBL] [Abstract][Full Text] [Related]
24. Good research practices for measuring drug costs in cost effectiveness analyses: an industry perspective: the ISPOR Drug Cost Task Force report--Part V.
Mycka JM; Dellamano R; Kolassa EM; Wonder M; Ghosh S; Hay JW; Smeeding J
Value Health; 2010; 13(1):25-7. PubMed ID: 19883402
[TBL] [Abstract][Full Text] [Related]
25. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report.
Garrison LP; Neumann PJ; Erickson P; Marshall D; Mullins CD
Value Health; 2007; 10(5):326-35. PubMed ID: 17888097
[TBL] [Abstract][Full Text] [Related]
26. Good research practices for measuring drug costs in cost-effectiveness analyses: a managed care perspective: the ISPOR Drug Cost Task Force report--Part III.
Mansley EC; Carroll NV; Chen KS; Shah ND; Piech CT; Hay JW; Smeeding J
Value Health; 2010; 13(1):14-7. PubMed ID: 19883404
[TBL] [Abstract][Full Text] [Related]
27. Approaches to Capturing Value in Oncology.
Walter E
Recent Results Cancer Res; 2019; 213():85-108. PubMed ID: 30543009
[TBL] [Abstract][Full Text] [Related]
28. A Health Economics Approach to US Value Frameworks: Serving the Needs of Decision Making.
Norman R; Chalkidou K; Culyer AJ
Value Health; 2018 Feb; 21(2):117-118. PubMed ID: 29477387
[No Abstract] [Full Text] [Related]
29. Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II.
Garrison LP; Mansley EC; Abbott TA; Bresnahan BW; Hay JW; Smeeding J
Value Health; 2010; 13(1):8-13. PubMed ID: 19883405
[TBL] [Abstract][Full Text] [Related]
30. Identification, Review, and Use of Health State Utilities in Cost-Effectiveness Models: An ISPOR Good Practices for Outcomes Research Task Force Report.
Brazier J; Ara R; Azzabi I; Busschbach J; Chevrou-Séverac H; Crawford B; Cruz L; Karnon J; Lloyd A; Paisley S; Pickard AS
Value Health; 2019 Mar; 22(3):267-275. PubMed ID: 30832964
[TBL] [Abstract][Full Text] [Related]
31. Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report.
Coons SJ; Gwaltney CJ; Hays RD; Lundy JJ; Sloan JA; Revicki DA; Lenderking WR; Cella D; Basch E;
Value Health; 2009 Jun; 12(4):419-29. PubMed ID: 19900250
[TBL] [Abstract][Full Text] [Related]
32. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
33. As Value Assessment Frameworks Evolve, Are They Finally Ready for Prime Time?
Dubois RW; Westrich K
Value Health; 2019 Sep; 22(9):977-980. PubMed ID: 31511186
[TBL] [Abstract][Full Text] [Related]
34. Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report--Part II.
Cox E; Martin BC; Van Staa T; Garbe E; Siebert U; Johnson ML
Value Health; 2009; 12(8):1053-61. PubMed ID: 19744292
[TBL] [Abstract][Full Text] [Related]
35. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
Williams I; Bryan S; McIver S
J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
[TBL] [Abstract][Full Text] [Related]
36. Health technology assessment and comparative effectiveness research: a pharmaceutical industry perspective.
Hao Y; Thomas A
Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):447-54. PubMed ID: 23977973
[TBL] [Abstract][Full Text] [Related]
37. Case studies that illustrate disinvestment and resource allocation decision-making processes in health care: a systematic review.
Polisena J; Clifford T; Elshaug AG; Mitton C; Russell E; Skidmore B
Int J Technol Assess Health Care; 2013 Apr; 29(2):174-84. PubMed ID: 23514665
[TBL] [Abstract][Full Text] [Related]
38. Good research practices for measuring drug costs in cost-effectiveness analyses: an international perspective: the ISPOR Drug Cost Task Force report--Part VI.
Shi L; Hodges M; Drummond M; Ahn J; Li SC; Hu S; Augustovski F; Hay JW; Smeeding J
Value Health; 2010; 13(1):28-33. PubMed ID: 19883403
[TBL] [Abstract][Full Text] [Related]
39. An economic framework for preventive care advice.
Pauly MV; Sloan FA; Sullivan SD
Health Aff (Millwood); 2014 Nov; 33(11):2034-40. PubMed ID: 25368000
[TBL] [Abstract][Full Text] [Related]
40. Clinical Guidelines: A NICE Way to Introduce Cost-Effectiveness Considerations?
Drummond M
Value Health; 2016; 19(5):525-30. PubMed ID: 27565268
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
